Post A Reply
my profile
login
|
register
|
search
|
faq
|
forum home
»
Allstocks.com's Bulletin Board
»
Micro Penny Stocks, Penny Stocks $0.10 & Under
»
MLSC NEWS............GREAT NEWS
» Post A Reply
Post A Reply
Login Name:
Password:
Message Icon:
Message:
HTML is not enabled.
UBB Code™ is enabled.
[QUOTE]Originally posted by dardadog: [QB] 2004-04-14 09:25:30 Medical Discoveries, Inc. Files Patent Application on Sepsis *** MDI Also Signs CMC Contract with Goodwin Laboratories TWIN FALLS, Idaho, April 14 /PRNewswire-FirstCall/ -- Medical Discoveries, Inc. (OTC Bulletin Board: MLSC) announced today that it has filed a provisional patent application on sepsis for MDI-P, its proprietary drug, as of March 17, 2004. The patent application was filed by Mayer, Brown, Rowe & Maw, patent counsel for MDI. Sepsis is a systemic inflammatory response to infection frequently caused by bacteremia, a condition wherein viable bacteria enter the bloodstream. The threat of cross-infection in hospital admissions is high (estimated at up to 30% of admissions), with the more serious cases leading to bacteremia and potentially sepsis. Consequently, where surgeries are proscribed, sepsis is a continuing threat to the more than 40 million surgery cases that occur in the United States each year. The US reports more than 200,000 sepsis deaths annually. In current preclinical trials, MDI-P is being evaluated for use as a surgical prophylactic or therapeutic agent for sepsis, as part of required research for an IND application for MDI's primary target, HIV/AIDS. If a safe, non-toxic therapeutic agent were available, a high percentage of the more than 40 million annual surgery cases (US, 2001 data) would likely receive such a therapeutic capable of preventing sepsis as a standard prophylactic procedure. However, in order to be qualified as a sepsis therapeutic agent, MDI-P would be additionally required to undergo another complete clinical development, through satisfactory Phase III clinical studies; a process which may take many years and require substantial investment. In another development related to the coming IND application, Medical Discoveries also announced the signing of a contract with Goodwin Biotechnology Inc., of Plantation, Florida, for the determination of complete Chemistry, Manufacturing and Control (CMC) documentation on MDI's proprietary electrolysis device, as well as the resultant MDI-P solution. At the end of this project, expected to take several months, MDI should have Current Good Manufacturing Practices (cGMP) qualification for the device and the solution, both of which are required prior to launching clinical studies on humans. The Goodwin work will become an important part of MDI's Investigational New Drug Application for conduct of Phase I clinical studies in HIV at Harvard Medical School. Formed in 1991, Medical Discoveries, Inc. is a publicly traded (OTC Bulletin Board: MLSC) development-stage biopharmaceutical research company (as defined in SFAS No.7) engaged in the research, development and validation of its patented anti-infective technology. MDI's electrolyzed solution of free radicals represents a novel approach to treating its initial target indication, HIV. Information in this press release relating to the potential of MDI constitutes forward-looking statements. Actual results in future periods may differ materially from the forward-looking statements because of a number of risks and uncertainties. Additional information about these and other factors that could affect MDI's business is set forth in MDI's 2003 Annual Report on Form 10-KSB and other filings with the Securities and Exchange Commission. SOURCE Medical Discoveries, Inc. -0- 04/14/2004 /CONTACT: Medical Discoveries, Inc., +1-208-736-1799/ /Web site: [URL=http://www.mdi-p.com]www.mdi-p.com[/URL] / (MLSC) CO: Medical Discoveries, Inc. ST: Idaho IN: MTC HEA BIO OTC SU: PDT CON [/QB][/QUOTE]
Instant Graemlins
Instant UBB Code™
What is UBB Code™?
Options
Disable Graemlins in this post.
*** Click here to review this topic. ***
Contact Us
|
Allstocks.com Message Board Home
© 1997 - 2021 Allstocks.com. All rights reserved.
Powered by
Infopop Corporation
UBB.classic™ 6.7.2